Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2013

Noonan Anne M, Eisch Robin A, Liewehr David J, Sissung Tristan M, Venzon David J, Flagg Thomas P, Haigney Mark C, Steinberg Seth M, Figg William D, Piekarz Richard L, Bates Susan E

Abstract excerpt

PURPOSE: Romidepsin is a histone deacetylase inhibitor (HDI) approved for the treatment of both cutaneous and peripheral T-cell lymphoma (CTCL and PTCL). During development, a thorough assessment of cardiac toxicity was conducted. EXPERIMENTAL DESIGN: A phase II single-agent nonrandomized study of romidepsin was conducted in patients with CTCL or PTCL who had progressed after at least 1 prior systemic therapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Depsipeptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Rate

Share to Histone Deacetylase Inhibitors

Share to Lymphoma, T-Cell, Cutaneous

Share to Lymphoma, T-Cell, Peripheral

Share to Magnesium

Share to Potassium

Source

Open in PubMed Open full text

Identifiers

PMID: 23589175
DOI: 10.1158/1078-0432.CCR-13-0109
PMCID: PMC6448401

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.PMID 23589175Read ↗

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumorsSemantic proximity Read ↗

Targeting histone deacetylases in T-cell lymphomaSemantic proximity Read ↗

Romidepsin for the treatment of cutaneous T-cell lymphomaSemantic proximity Read ↗

Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative dataSemantic proximity Read ↗

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphomaSemantic proximity Read ↗

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.Semantic proximity Read ↗

Interventions with Potential to Mitigate Injection Site Reactions Following Subcutaneous Elamipretide Administration: A Phase 1, Crossover StudySemantic proximity Read ↗

Impact of ABCB1 allelic variants on QTc interval prolongation.Semantic proximity Read ↗

Interventions with Potential to Mitigate Injection Site Reactions Following Subcutaneous Elamipretide Administration: A Phase 1, Crossover StudySemantic proximity Read ↗

Phase II trial of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin in elderly transplant-ineligible patients with relapsed/refractory peripheral T- cell lymphomaSemantic proximity Read ↗

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomasSemantic proximity Read ↗

Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.